Arab Health 2020 to Showcase Innovative Non-Opioid Pain Blocking Technology


A ground-breaking non-opioid pain therapy solution that blocks pain for up to 24 hours will be showcased on the ABHI UK pavilion at Arab Health 2020.

BioWave provides a unique way of utilising electrical nerve stimulation at the source – using a special signal-mixing technology to penetrate muscle tissue through the skin and prevent pain from reaching the brain.

Described as ‘non-opioid’, the medical device provides a drug-free alternative to pain management and is clinically proven to block chronic and acute pain on most locations of the body – including the back, neck, shoulder, knee, and elbow.

Used by trainers and physical therapists, BioWave offers many benefits for both patients and clinicians, including reducing the need for potentially addictive medication prescriptions and promoting longer lasting pain-relief.

Brad Siff, Founder & President of BioWave, commented: “For patients, BioWave can provide up to 24 hours of pain relief from just one 30-minute treatment with the non-invasive electrodes, or up to 72 hours with a percutaneous electrode. With the continued use of BioWave, patients will also be able to reduce any medication they might be on – without fear of side effects or overdosing. More critically, it means clinicians will not be prescribing as many opioids as before.

Steve Dechan, MD of Platform-14, who hold the distribution rights of Biowave across EMEA added: “The clever thing with BioWave is that, unlike traditional electrical nerve stimulation, it uses a smart ‘signal-mixing technology’ that penetrates the skin into deep tissue to block pain at its source, providing longer-lasting pain relief. We are delighted to be launching the product at Arab Health 2020.”

Clinical studies show that more than 84% of patients experience a significant reduction in pain using BioWave. It has been used successfully by doctors, physical therapists and athletic trainers – including to treat pain from acute and chronic tendinopathies, joint sprains, osteoarthritis, and post-operative pain.

Following eight years of prototypes and clinical studies, the device obtained FDA Marketing Clearance for the U.S in 2008. In late 2007, The New York Football Giants American Football team became Brad’s first customer. Today, hundreds of professional and college sports teams use BioWave to keep athletes in the game, and it is used in over 150 VA Hospitals and military bases around the United States.

The product is set to be launched in the UK and the Middle East during 2020.

Paul Benton, Managing Director, International at the ABHI commented: “We are looking forward to welcoming Platform 14 on the ABHI pavilion at Arab Health. Their pioneering device is just one of the many exciting smart technological solutions for healthcare that will be showcased on the UK pavilion next year.”

Arab Health is taking place from 27 – 30 January 2020 and throughout the show, Platform 14 will be located on the ABHI UK Pavilion - hall 2 Stand F57.